Literature DB >> 12756140

Depression as a risk factor for Alzheimer disease: the MIRAGE Study.

Robert C Green1, L Adrienne Cupples, Alex Kurz, Sanford Auerbach, Rodney Go, Dessa Sadovnick, Ranjan Duara, Walter A Kukull, Helena Chui, Timi Edeki, Patrick A Griffith, Robert P Friedland, David Bachman, Lindsay Farrer.   

Abstract

BACKGROUND: Depression symptoms may be associated with the development of Alzheimer disease (AD).
OBJECTIVES: To evaluate the association between depression symptoms and risk of AD, and to explore the temporal aspects of this association.
SETTING: Academic institutions with specialized memory clinics.
DESIGN: Cross-sectional, family-based, case-control study with standardized self- and proxy questionnaires to collect information on depression symptoms and other risk factors. PARTICIPANTS: A total of 1953 subjects with AD and 2093 of their unaffected relatives enrolled in the Multi-institutional Research in Alzheimer's Genetic Epidemiology Study. MAIN OUTCOME MEASURES: Odds ratios (ORs) of AD were estimated with and without depression symptoms, adjusted for age, sex, education, history of head trauma, and apolipoprotein E status.
RESULTS: There was a significant association between depression symptoms and AD (adjusted OR, 2.13; 95% confidence interval [CI], 1.71-2.67). In families where depression symptoms first occurred within 1 year before the onset of AD, the association was higher (OR, 4.57; 95% CI, 2.87-7.31), while in the families where the depression symptoms first occurred more than 1 year before the onset of AD, the association was lower (OR, 1.38; 95% CI, 1.03-1.85). In families where depression symptoms first occurred more than 25 years before the onset of AD, there was still a modest association (OR, 1.71; 95% CI, 1.03-2.82).
CONCLUSIONS: Depression symptoms before the onset of AD are associated with the development of AD, even in families where first depression symptoms occurred more than 25 years before the onset of AD. These data suggest that depression symptoms are a risk factor for later development of AD.

Entities:  

Mesh:

Year:  2003        PMID: 12756140     DOI: 10.1001/archneur.60.5.753

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  157 in total

1.  Incidence and risk factors for cognitive impairment no dementia and mild cognitive impairment in African Americans.

Authors:  Frederick W Unverzagt; Adesola Ogunniyi; Vanessa Taler; Sujuan Gao; Kathleen A Lane; Olusegun Baiyewu; Oye Gureje; Valerie Smith-Gamble; Ann Hake; Hugh C Hendrie; Kathleen S Hall
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

2.  Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II study.

Authors:  Archana Singh-Manoux; Tasnime N Akbaraly; Michael Marmot; Maria Melchior; Joël Ankri; Séverine Sabia; Jane E Ferrie
Journal:  J Clin Psychiatry       Date:  2010-06-01       Impact factor: 4.384

3.  Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.

Authors:  Charles F Reynolds; Meryl A Butters; Oscar Lopez; Bruce G Pollock; Mary Amanda Dew; Benoit H Mulsant; Eric J Lenze; Margo Holm; Joan C Rogers; Sati Mazumdar; Patricia R Houck; Amy Begley; Stewart Anderson; Jordan F Karp; Mark D Miller; Ellen M Whyte; Jacqueline Stack; Ariel Gildengers; Katalin Szanto; Salem Bensasi; Daniel I Kaufer; M Ilyas Kamboh; Steven T DeKosky
Journal:  Arch Gen Psychiatry       Date:  2011-01

Review 4.  Cognitive functioning and late-life depression.

Authors:  Aaron M Koenig; Rishi K Bhalla; Meryl A Butters
Journal:  J Int Neuropsychol Soc       Date:  2014-03-31       Impact factor: 2.892

5.  Protein binding in patients with late-life depression.

Authors:  Anand Kumar; Vladimir Kepe; Jorge R Barrio; Prabha Siddarth; Vicki Manoukian; Virginia Elderkin-Thompson; Gary W Small
Journal:  Arch Gen Psychiatry       Date:  2011-11

6.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

7.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Non-cognitive psychopathological symptoms associated with incident mild cognitive impairment and dementia, Alzheimer's type.

Authors:  Antonio Lobo; Raúl López-Antón; Concepción de-la-Cámara; Miguel Angel Quintanilla; Antonio Campayo; Pedro Saz
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.

Authors:  Raymond L Ownby; Elizabeth Crocco; Amarilis Acevedo; Vineeth John; David Loewenstein
Journal:  Arch Gen Psychiatry       Date:  2006-05

10.  Gene-behavior interaction of depressive symptoms and the apolipoprotein E {varepsilon}4 allele on cognitive decline.

Authors:  Kumar B Rajan; Robert S Wilson; Kimberly A Skarupski; Carlos F Mendes de Leon; Denis A Evans
Journal:  Psychosom Med       Date:  2014-01-16       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.